Findings

What do systematic reviews say?

70 questions · 71 findings · 6 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 28.2%GRADE not reported 5 · 7%Very low 21 · 29.6%Low 9 · 12.7%Moderate 13 · 18.3%High 3 · 4.2%

IVIg vs placebo

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 78 participants
GRADE not reported

Intravenous thyrotropin releasing hormone vs placebo

Change in disability score · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous thyrotropin releasing hormone vs placebo

Muscle strength · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Very low

Intravenous thyrotropin releasing hormone vs placebo

Acquiring the ability to stand or walk · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous thyrotropin releasing hormone vs placebo

Change in quality of life · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous thyrotropin releasing hormone vs placebo

Change in pulmonary function · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous thyrotropin releasing hormone vs placebo

Time from birth until death or full‐time ventilation · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Intravenous thyrotropin releasing hormone vs placebo

Adverse events related to treatment · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Very low

Corticosteroids vs control

Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome

1 finding from 1 review

Corticosteroids for Guillain‐Barré syndrome 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 467 participants
Moderate

Interferon beta‐1a vs placebo

Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

Brain‐derived neurotrophic factor vs placebo

Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Brain‐derived neurotrophic factor vs placebo

Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 5 participants
Very low

Brain‐derived neurotrophic factor vs placebo

Death · patients with Guillain‐Barré syndrome

It is very uncertain whether brain‐derived neurotrophic factor changes death compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 0.67 [0.06, 7.85]
1 study · 10 participants
Very low

Brain‐derived neurotrophic factor vs placebo

Death or disability after 12 months · patients with Guillain‐Barré syndrome

It is very uncertain whether brain‐derived neurotrophic factor changes death or disability after 12 months compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.33 [0.17, 10.25]
1 study · 10 participants
Very low

Brain‐derived neurotrophic factor vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1 [0.28, 3.54]
1 study · 10 participants
Very low

Cerebrospinal fluid filtration vs plasma exchange

Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Very low

Cerebrospinal fluid filtration vs plasma exchange

Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome

It is very uncertain whether cerebrospinal fluid filtration changes improvement in disability grade Defined as achievement of a… compared with plasma exchange (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 0.94 [0.48, 1.84]
1 study · 37 participants
Very low

Cerebrospinal fluid filtration vs plasma exchange

Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Very low

Cerebrospinal fluid filtration vs plasma exchange

Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cerebrospinal fluid filtration vs plasma exchange

Death · patients with Guillain‐Barré syndrome

Cerebrospinal fluid filtration showed no clear difference in death compared with plasma exchange (low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.18 [0.08, 17.42]
1 study · 37 participants
Low